Your browser version may not work well with NCBI's Web applications. More information here...
1: Arthritis Res Ther. 2006;8 Suppl 2:S3. Epub 2006 Jul 28.
Related Articles, Links
Click here to read
Interleukin-6 and chronic inflammation.

Gabay C.

Division of Rheumatology, University Hospital of Geneva, Switzerland. cem.gabay@hcuge.ch

Interleukin (IL)-6 is produced at the site of inflammation and plays a key role in the acute phase response as defined by a variety of clinical and biological features such as the production of acute phase proteins. IL-6 in combination with its soluble receptor sIL-6Ralpha, dictates the transition from acute to chonic inflammation by changing the nature of leucocyte infiltrate (from polymorphonuclear neutrophils to monocyte/macrophages). In addition, IL-6 exerts stimulatory effects on T- and B-cells, thus favoring chronic inflammatory responses. Strategies targeting IL-6 and IL-6 signaling led to effective prevention and treatment of models of rheumatoid arthritis and other chronic inflammatory diseases.

Publication Types:
PMID: 16899107 [PubMed - indexed for MEDLINE]